



**Annual
Report**

2025

**Sustainable strategic
development**



The Custodian of the Two Holy Mosques
King Salman bin Abdulaziz Al Saud

May Allah preserve him

My primary goal is for our country to become a successful and leading global model across all levels, and I will work with you to achieve this. ”



His Royal Highness
Prince Mohammed bin Salman bin Abdulaziz Al Saud

Crown Prince, Prime Minister, and Chairman of the Council of Economic and Development Affairs

May Allah preserve him.

I am pleased to present to you the vision of the present for the future—one that we wish to start implementing today for tomorrow, reflecting our collective ambitions and the capabilities of our nation. ”



AME

AME Company for
Medical Supplies

Table of Contents

01

Chairman's Statement

02

CEO's Statement

03

About AME Company

04

The Company's Board of Directors and its Committees

05

Company's Main Activities and Segments

06

Challenges and Risks

07

Financial Results for the year 2025G

08

Dividend

09

Annual Audit Committee Report

10

Corporate Governance



Chairman's Statement
Faisal bin Mohammed Al-Omran

In the Name of Allah, the Most Gracious, the Most Merciful
Dear Valuable Shareholders,
Peace, blessings, and mercy of Allah be upon you,

It gives me immense pleasure to share with you the Board of Directors' report for AME Company for Medical Supplies for the fiscal year ending December 31, 2025. This year witnessed strong sales growth, reflecting the company's robust market presence and diversified portfolio, and underscoring its promising operational base and future growth potential.

This performance was achieved in a challenging and volatile business environment, necessitating a high degree of disciplined monitoring, meticulous execution, and a focus on building a more solid and sustainable foundation for growth. Therefore, the Board's focus was not solely on the volume of growth, but also on its quality, the quality of its profits, and its tangible impact on the company's financial position and cash flow.

The Board believes that achieving sustainable shareholder value depends not only on expansion, but also on a balance between growth, profitability, asset quality, and financial discipline. Accordingly, since assuming its duties in August 2025, the Board has focused on establishing a more rigorous corporate approach to governance and oversight, and enhancing the efficiency of decision-making, thereby supporting the company's long-term interests and strengthening its resilience to risks and fluctuations.

The Board has adopted a clear vision for the next phase: maximizing the company's sustainable value through effective governance, robust corporate operations, greater efficiency in spending and investment, and enhanced earnings quality and financial position.

In this context, the Board has focused on several key areas, most notably:

01 | Developing Governance and Corporate Operations

Seeking to develop internal policies and regulations, enhancing the effectiveness of Board committees, and strengthening internal control and risk management frameworks, thereby reinforcing the principles of transparency and accountability and protecting shareholders' rights.

02 | Enhancing Earnings Quality and Financial Position

The Board also paid special attention to asset quality and earnings quality by strengthening working capital management discipline, reviewing the quality and collectability of receivables, and adopting a more conservative and accurate approach to estimating expected credit losses. This supports the company's financial strength and enhances the sustainability of its results.

03 | Improving Investment Efficiency and Capital Allocation

Adopting a disciplined approach to evaluating investment opportunities and allocating capital, focusing on initiatives that generate attractive returns and support the company's long-term value, while considering operational and financial priorities.

04 | Improving Spending Efficiency and Cost Structure

Reviewing cost items and improving resource utilization efficiency contributes to improved profitability and supports the company's competitiveness without compromising operational quality or growth requirements.

05 | Supporting Selective and Controlled Growth

Endeavoring to enhance operational efficiency, develop products and services, and expand in a well-considered manner, balancing the pursuit of business opportunities with maintaining financial discipline and asset quality.

Looking ahead to 2026, the Board of Directors affirms that its primary priorities include enhancing profitability and its quality, improving the quality of operating cash flows, and increasing the efficiency of working capital management. This will be coupled with adopting a more balanced and efficient financing structure, supporting sustainable growth and maintaining the company's strong financial position.

The Board also emphasizes its commitment to continued effective oversight of strategy implementation, strengthening governance, control, and corporate discipline, and establishing a more efficient and sustainable business model that positively impacts the company's value and the interests of its shareholders and all stakeholders.

While appreciating the efforts of the executive management and company employees during the year, the Board underscores the importance of the next phase in solidifying a culture of responsible performance, financial discipline, and high-quality execution. This will align with shareholder expectations and foster sustainable growth.

In conclusion, I extend my sincere thanks and appreciation to our valued shareholders for their continued trust and support, to our clients and partners, and to all company employees for their efforts throughout the year. We ask God for success and guidance in all that is good for the company and its shareholders.

With highest regards,
Faisal bin Mohammed Al-Omran
 Chairman



CEO's Statement
Abdelfattah Abdallah Ahmed

In the Name of Allah, the Most Gracious, the Most Merciful
Dear Valuable Shareholders,
Peace, blessings, and mercy of Allah be upon you,

I am pleased to present an overview of **AME Company for Medical Supplies** performance during 2025G. This performance is the result of integrated efforts between the Board of Directors, the Executive Management, and the work teams, while maintaining the highest levels of quality and compliance, enhancing operational efficiency, and strengthening financial discipline.

Throughout 2025G, the Executive Management focused on implementing clear strategic priorities, which were reflected in the company's overall performance. The most notable of these priorities are summarized below:



Financial & Operational Performance

AME Medical Equipment and Devices Company achieved strong revenue growth during the 2025 fiscal year, as revenues increased by 22.8% to reach SAR 304.96 million, compared to SAR 248.35 million in the previous year, driven by market expansion and higher sales of relatively new products, alongside the company's success in strengthening its commercial presence and diversifying its revenue streams.

At the net profit level, the net profit attributable to the company's shareholders reached SAR 35.01 million, compared to SAR 45.40 million in the previous year. This decline is primarily due to recording higher provisions for expected credit losses as a result of the company adopting a more conservative approach in assessing the quality and collectability of accounts receivable, thereby enhancing asset quality and the robustness of the financial position. Results were also affected by an increase in professional and legal fees related to special-nature works and audits during the year, in addition to higher financing costs associated with short-term facilities used to support working capital.

Furthermore, the company continued to support its operational growth by increasing investment in working capital, particularly in inventory and accounts receivable, while maintaining appropriate financial flexibility through a balanced mix of operational cash flows and short-term banking facilities.



Digital Transformation and Innovation

The year witnessed progress in digital transformation initiatives through the development of the company's internal systems to support robust decision-making and increased productivity.



Human Resources

We worked on developing capabilities and building more agile teams through training programs, performance appraisals, and organizational improvements, while fostering a culture of commitment and efficiency.

Looking ahead to 2026G, our priorities are centred around:

- 01** Accelerating balanced business growth,
- 02** Enhancing profitability through increasing efficiency and cost management,
- 03** Increasing maturity in governance, risk management, and compliance,
- 04** Completing digital transformation initiatives and linking them to clear performance indicators,
- 05** Enhancing the customer experience and developing service channels.

In conclusion, I would like to thank the Board of Directors for their guidance and support, our valued shareholders for their trust, all company employees for their dedication and efforts, and our customers and partners for their continued cooperation. We pray for success in fulfilling your aspirations and maximizing the company's long-term value.

Please accept our highest regards and appreciation,

Abdelfattah Abdallah Ahmed
CEO

A woman's face is shown in a close-up, looking slightly to the right. Several hands wearing white medical gloves are touching her face, suggesting a medical examination or procedure. The entire image has a blue color cast.

01

**About AME
Company for
Medical Supplies**

AME



2005

AME Company for Medical Supplies started its journey in supplying medical equipment and devices to the cosmetic market from its head office in Jeddah, Kingdom of Saudi Arabia in 2005, leveraging its deep knowledge and expertise in the needs and requirements of this industry and its customers in the Kingdom. The Company adopts a research and development methodology in conducting in-depth studies of the needs of this industry and its promising future, and its great keenness to extend its knowledge of the latest advances in global technology in this field.

In 2008, the company became the official authorized representative of TEOXANE, a manufacturer of a comprehensive range of hyaluronic acid-based dermal fillers, produced to the highest quality and safety standards in its laboratories in Geneva, Switzerland. Also in 2008, the company was accredited as the official representative of DEKA, a leader for over 30 years in medical laser systems and the development of innovative treatments worldwide, contributing to improved physician efficiency and enhanced patient comfort.


The Company has managed to develop its strategy and implementation mechanisms, in line with the Government's persistent efforts to apply the concept of quality of life and generalize it to various aspects of life as one of the paths to achieving the programs of the Kingdom's Vision 2030, based on its deep medical, health and investment expertise and knowledge and increasing the interest of community members in the concept of beauty and health. The company has also succeeded in building and developing a wide range of strategic partnerships with the most prominent providers of the most advanced medical materials, equipment, and supplies in the world, to become their exclusive supplier throughout the Kingdom of Saudi Arabia. This earned it a distinguished leadership position in the Kingdom in this promising health sector.

As part of its ongoing expansion, the company became the authorized distributor of the Magellan system in 2017. Magellan is a self-concentrating system that provides platelet and cell concentrating care and is used in aesthetic medicine and soft surgery. Its authorized distributorship portfolio also included (Novavision) and (Mesojet). In 2023, the company became the authorized distributor for (Nabota), related to AntiAge products and Euromi devices. The company continued to expand its product portfolio, becoming the authorized distributor for Quantificare and ExoSmart in 2024.

The approval of the company's ordinary general assembly of the Board of Directors' recommendation to transfer the company from the Saudi Parallel stock market (Nomu) to the Main Market represents an ambitious strategic step toward consolidating its leading position in the Kingdom and supporting its solvency and financial strength, which will enable it to expand its base of shareholders and customers, and increase its promising investment portfolio with more profitable returns for all shareholders and partners.

Company at a Glance

Organization Structure



Year's **2025** Highlights

Election of a new Board of Directors for a second term, commencing July 31, 2025G for a period of four years.

Approval by the company's Ordinary General Assembly of the Board of Directors' recommendation to distribute 20% dividends for the year 2024G.

Approval by the company's Ordinary General Assembly of the Board of Directors' recommendation to distribute 20% dividends for the year 2024G.

Company expansion through establishing branches within the Kingdom.

Executive Summary

Key Financial and Operational Indicators

AME Medical Equipment and Devices Company achieved strong revenue growth during the 2025 fiscal year, as revenues increased by 22.8% to reach SAR 304.96 million, compared to SAR 248.35 million in the previous year. This growth was driven by market expansion and higher sales of relatively new products, alongside the company's success in strengthening its commercial presence and diversifying its revenue streams.

The company also recorded a notable improvement in the gross profit margin, which rose from 41.1% to 42.1%, clearly indicating the quality of growth, an improved sales mix, and operational efficiency. Consequently, gross profit increased by 25.8% to reach SAR 128.49 million, compared to SAR 102.16 million in the previous year.


At the net profit level, the net profit attributable to the company's shareholders reached SAR 35.01 million, compared to SAR 45.40 million in the previous year. This decline is primarily attributed to recording higher provisions for expected credit losses as a result of the company adopting a more conservative approach in assessing the quality and collectability of accounts receivable, thereby enhancing asset quality and the robustness of the financial position. Results were also affected by an increase in professional and legal fees related to special-nature works and audits during the year, in addition to higher financing costs associated with short-term facilities used to support working capital.

Despite this impact on net profit, the results reflect the continued strength of the company's operational performance, supported by revenue growth and improved gross profitability, alongside the adoption of more conservative financial and accounting policies aimed at enhancing earnings quality and financial position solidity.

Furthermore, the company continued to support its operational growth by increasing investment in working capital, particularly in inventory and accounts receivable, while maintaining appropriate financial flexibility through a balanced mix of operational cash flows and short-term banking facilities.

The company affirms its continued focus during the coming phase on sustainable growth, earnings quality, discipline in working capital management, and enhancing asset quality to support its financial position over the medium and long term.


Stock Performance





Mission

We are committed to providing high-quality, innovative brands and services that meet the needs of patients and healthcare providers in the medical aesthetics sector in the Kingdom of Saudi Arabia. We endeavour to complete all work, through our commitment to a code of work ethics and transparency in a safe work environment, through which we attract advanced technical and medical expertise, to create sustainable value.




Vision

Developing partnerships with suppliers and entering new partnerships based on market requirements to provide distinguished products and high-quality services through a work team of specialized professionals.



AME Company For Medical Supplies is committed to implementing a sustainable development strategy, through which it seeks to raise the efficiency of operational and financial performance to achieve the highest profitable returns for all shareholders and partners and in a way that ensures the strengthening of its unique leadership position in the cosmetic health industry in the Kingdom of Saudi Arabia. The Company's strategy is based on the following pillars:



The first pillar

Increasing its market share of its main activities in the Kingdom of Saudi Arabia and developing the customer base.

The second pillar

Developing its operations by entering new partnerships with international suppliers and expanding its product base.

The third pillar

Studying entering into other value-added business lines that are consistent with the company's current business.

The fourth pillar

Developing the Company's current business model by taking advantage of its expertise in the market and customer base, expanding horizontally and vertically, increasing business volume and revenues, and achieving higher profitability rates for shareholders.

Strategy Implementation Pillars

Company Strategy



Competitive Advantages

AME Company For Medical Supplies is unique in having a wide presence and a true leadership position in the cosmetic medicine industry sector, based on a set of competitive advantages that can be summarized as follows:

- 01** Extensive experience and great knowledge of the requirements and needs of the cosmetic medicine industry sector, as a pioneer of this industry for several decades in the Kingdom of Saudi Arabia.
- 02** Attracting a medical, technical, operational, and investment team of the best competencies, talents, skills, knowledge, and distinguished experiences in their field.
- 03** Unique operational excellence, in a stimulating competitive work environment, that ensures the stability of the job cycle, ensuring the highest levels of loyalty and belonging among all employee segments, which raises performance and maximizes achievement, to achieve the Company's strategic goals.
- 04** Its great success in building the best strategic relationships with the most prominent global providers of services, products, equipment, and supplies, coupled with its efficiency in developing and sustaining them.
- 05** Its footprint and geographical presence in the most prominent markets of the Kingdom, give it the ability, efficiency, and flexibility to meet all the requirements and needs of all segments of its customers, with the required speed and quality.



Operating Model

AME Company For Medical Supplies applies an advanced operating model that ensures its distinction and uniqueness by providing the best solutions, services, and the latest products globally to all segments of its customers in the Kingdom. The model can be represented as follows:

01 Conducting in-depth research and studies for the current and future needs of the cosmetic medicine industry in the Kingdom.

02 Attracting, developing, supporting, and empowering the best medical and technical competencies, skills, and expertise.

03 Building and sustaining the best strategic partnerships with the most prominent providers of global cosmetic medical services, products, supplies, and equipment.

04 Providing the most modern, advanced, and efficient international services, products, equipment and cosmetic medical supplies to all segments of our customers and supporting them with high-quality after-sales services.

05 Introducing new business lines in a very carefully considered manner, in a way that is compatible with its business and activities, in a way that gives the Company added value in everything it offers to all segments of its customers.

Strategic Goals and Aspirations

- 01** AME Company for Medical Supplies aims to grow its market share in the Kingdom of Saudi Arabia in a sustainable manner while focusing on its core activities (fillers, lasers, and platelet-rich plasma), as it has a strong and mature base of large, established customers.
- 02** AME Company for Medical Supplies aims to grow its market share by expanding into the GCC countries during 2026.
- 03** Growing and sustaining revenues and profit margins.
- 04** Achieving the highest levels of customer satisfaction and retention.
- 05** Developing employees and empowering them in a competitive, stimulating work environment.
- 06** Enhancing the strength and position of the Company's brand and enabling it to lead the market.
- 07** Regulatory compliance and ethical business practices.



Footprint and Geographical Presence



In an effort to ensure the provision of its quality services and products to all segments of its customers and its proximity to them throughout all regions of the Kingdom, the Company owns, in addition to its head office in Jeddah, multiple branches across the kingdom as follows:




Jeddah
(Head Office)

Qassim Branch

Dammam Branch

Riyadh Branch

Abha Branch



2026G



2026G Plan

In 2025G, the Board of Directors recommended relocating the main branch from Jeddah to Riyadh. This move aims to enhance the company's proximity to decision-making centers, regulatory bodies, and strategic clients, thereby increasing responsiveness, improving growth and partnership opportunities, and facilitating the recruitment of leading and specialized talent. This will support the company's readiness for the next phase and enhance operational efficiency across the Kingdom.

The Board also approved the Executive Management's plan for expansion into GCC markets. This strategic direction aims to strengthen the company's regional presence and competitive position, and to meet the aspirations of strategic partners seeking to expand AME Company for Medical Supplies' reach beyond the Kingdom. This expansion will support business growth and sustainability in the medium and long term.



02

**The Company's
Board of Directors
and Committees**

AME



Board of Directors



The Board of Directors' first term ended on July 30, 2025G. following the Extraordinary General Assembly's approval on May 25, 2025G. of a resolution to terminate the first term, based on the Board's recommendation. At the Ordinary General Assembly held on July 27, 2025G. the Board members for the second term were elected as follows:

Member name	Membership Classification
Mr. Faisal bin Mohammad Al-Omran	Non-executive member
Mr. Abdulaziz bin Saleh Aloamir	Non-executive member
Dr. Ali bin Mohammed Deeb Ali Eid	Executive member
Mrs. Latifa bint Abdul Rahman Al-Hudaib	Independent member
Mr. Khalid bin Saeed Al-Safri	Independent member

The Board of Directors is appointed by the shareholders, and it has the broadest powers to manage the company, direct its business to achieve its objectives, and set plans, policies, strategies, and main objectives for the company, considering the long-term interest of shareholders. The Board of Directors is composed of six members and a Secretary of the Board, who are elected by the General Assembly of the Company. Below are the names and positions of the members, and their membership classification:

Biographies of the Board Members

Faisal bin Mohammad Al-Omran



Position

Chairman of the Board

About the member

Mr. Faisal Al-Omran has nearly 25 years of professional experience in the banking and investment sector, during which he held leadership positions in local and international financial and investment institutions in Saudi Arabia, the Gulf region and Europe. He possesses extensive experience in asset management, institutional investment, finance and deal structuring, risk management, and financial markets, in addition to advanced expertise in corporate governance and board membership.

Mr. Al-Omran holds a Bachelor of Science degree in Accounting from King Saud University and a Master of Business Administration (MBA) from London Business School.

Academic Qualification

Mr. Al-Omran holds a Bachelor of Science degree in Accounting from King Saud University and a Master of Business Administration (MBA) from London Business School.

Current Executive Positions

- Chairman of the Board of Directors of AME Company for Medical Supplies – JSC
- Member of the Board of Directors of Bonyan REIT Fund – an exchange-traded fund
- Vice Chairman of the Board of Directors of Sadara Capital
- Member of several specialized committees

Abdulaziz bin Saleh Aloamir



Position

Deputy Chairman of the Board

About the member

Mr. Abdulaziz has over 20 years of professional experience in the banking and investment sector, during which he held leadership and executive positions in leading financial and investment institutions in Saudi Arabia. He possesses expertise in investment management, private equity, business development, and client relationship management, along with advanced experience in corporate governance and serving on boards of directors and specialized committees.

Academic Qualification

Mr. Abdul Aziz holds a Bachelor's degree in Business Administration from Webster University in Switzerland.

Current Executive Positions

- Vice Chairman of the Board of Directors of AME Company for Medical Supplies – JSC
- Member of the Board of Directors of Wasl Investment Trading Company – CJSC
- Chairman of the Board of Directors of Arab Cooperative Insurance Company JSC
- Chairman of the Board of Directors of Bidaya Finance Company – CJSC
- Chairman of the Board of Directors of Saudi Galvanizing Company (Gulfanco) – CJSC
- Member of the Board of Directors of Al Rajhi Financial Investment Funds – CJSC
- Member of the Board of Directors of Al Rajhi REIT Fund – CJSC
- Chairman of the Board of Directors of Al Maalouma International Information Technology Company – Limited Liability Company
- Owner of Muhimma Digital Communications and Information Technology Company – Limited Liability Company
- Member of the Board of Directors of Musheed Arabia Company – CJSC
- Member of several specialized committees

Ali bin Mohammed Deeb Ali Eid



Position

Board member and Managing Director

About the member

Dr. Ali Eid has over 20 years of professional experience in the medical sector and the supply and trading of medical equipment and devices, during which he held leadership and executive positions within the Kingdom of Saudi Arabia. He possesses expertise in executive management and business development within the healthcare sector, as well as experience in corporate governance and serving on boards of directors and executive committees.

Academic Qualification

Dr. Ali Eid holds a Bachelor of Medicine degree from Damascus University in Syria and a professional diploma in clinical nutrition from the National Nutrition Institute in Egypt.

Current Executive Positions

- Managing Director, AME Company for Medical Supplies – JSC
- Owner of Al-Naqa Pharmaceutical Medical Company – a Limited Liability Company

Khalid bin Saeed Al-Safri



Position

Board member

About the member

Professor Khaled Al-Safri has over 15 years of professional experience in the legal field, during which he held professional and executive roles in law practice and legal consulting within the Kingdom of Saudi Arabia. He also possesses expertise in legal affairs and governance through his participation in professional memberships and specialized committees, in addition to his experience serving on boards of directors.

Academic Qualification

Mr. Khaled Al-Safri holds a Bachelor's degree in Systems from King Abdulaziz University and a Master's degree in Law and Professional Practice from King Abdulaziz University.

Current Executive Positions

- Board Member of AME Company for Medical Supplies – JSC

Latifa bint Abdul Rahman Al-Hudaib



Position

Board member

About the member

Ms. Latifa Al-Hudaib has over 10 years of professional experience in governance, risk management, compliance, and investment, during which she has held leadership and advisory positions in governmental, semi-governmental, and corporate entities in Saudi Arabia. She also possesses expertise in finance, credit risk management, and organizational excellence, along with advanced experience in corporate governance and serving on boards of directors and specialized committees.

Academic Qualification

Professor Latifa holds a Bachelor's degree in Botany/Microbiology from King Saud University, a Master's degree in Finance from Dublin City University, and an ISDE Global Master's degree in Sports Management and Legal Skills from FC Barcelona.

Current Executive Positions

- Board Member of AME Company for Medical Supplies – JSC
- Chairman of the Board of Directors of Esnad Financial Company – Limited Liability Company
- Board Member of Investors Financial Company – CJSC
- Board Member of Winstone Capital Company – CJSC
- Member of several specialized committees



Board of Directors' Responsibilities:

According to Articles (20) and (21) of the Corporate Governance charter, the Board of Directors holds full responsibility for managing the company and representing all shareholders. Board members are obligated to exercise due diligence and loyalty in a manner that serves the company's best interests and maximizes its value. The Board remains responsible for the company's operations even when some of its powers are delegated, provided that the delegation is not general or indefinite (Article 20). The Board also performs its core functions of approving the strategy, plans, policies, and objectives and overseeing their implementation; approving budgets and organizational structures; establishing internal control, risk management, governance, and compliance systems; ensuring the integrity of financial and accounting systems and the accuracy of disclosures and reports; approving financial statements and the Board of Directors' report before their publication; regulating the relationship with stakeholders; forming Board committees, defining their powers, and evaluating them; and submitting necessary recommendations to the General Assemblies on material matters such as capital changes, dividend, and reserves (Article 21).

01 Audit Committee

The current Audit Committee was formed in accordance with Article Five of the Audit Committee Charter. The charter was approved by the Ordinary General Assembly in its meeting held on 17 /12 /1445H corresponding to 23 /06/ 2024G Accordingly, the Board of Directors decided on 032025/08/G to form an Audit Committee, provided that the Audit Committee's term shall begin on Thursday 31/ 07 /2025G and end with the end date of the Board of Directors' term. The committee for the third term was formed as follows:

Member Name	Position Membership Classification
Mr. Saleh bin Abdullah Al Qraisha	(Independent member) as Chairman of the Committee
Mr. Hattan bin Abdul Wahab Al-Qahtani	(Independent member) as a committee member
Mr. Nawaf bin Khalid Al-Aidan	(Independent member) as a committee member

Biographies of the Audit Committee Members

Saleh bin Abdullah Al Qraisha



Position

Chairman of the Committee

About the member

Mr. Saleh bin Abdullah Al-Quraisha possesses extensive leadership experience in investment, finance, company formation, and growth, with a distinguished professional track record in cash flow management, financing, acquisitions, valuation, restructuring, and building strategic alliances. He also has advanced expertise in corporate governance through his participation on boards of directors and specialized committees across multiple sectors, supported by broad experience in the Saudi banking sector, as well as the real estate, healthcare, education, and hospitality sectors.

Academic Qualification

- Bachelor's degree from the College of Industrial Management, King Fahd University of Petroleum and Minerals
- Master's degree in Finance.

Current Executive Positions

- CEO of Nahaz Investment Company.
- Chairman of the Audit Committee at AME Company for Medical Supplies – JSC
- Board Member of Dallah Healthcare Company, Member of the Finance and Investment Committee, Member of the Nominations and Remuneration Committee.
- Board Member of Yanal Finance Company (Oryx), Member of the Executive Committee, Member of the Nominations and Remuneration Committee.
- Board Member of Ksayes Inters Contracting Company.
- Board Member of Raqmat Development Company (a government-owned company).
- Member of the Audit Committee at Arab Cooperative Insurance Company.

Hattan bin Abdul Wahab Al-Qahtani



Position

Audit Committee Member

About the member

A Certified Public Accountant (CPA, SOCPA), with extensive experience in financial control and auditing exceeding 7 years, including 5 years in major international accounting firms, currently holds the position of Director of Finance at Awqaf Management and Real Estate Services Company. He has previously worked in leading companies such as the Saudi Stock Exchange Group, ACWA Power, EY and KPMG, and has experience in team management, improving financial processes, and dealing with regulatory authorities.

Academic Qualification

Mr. Hattan Al-Qahtani holds a Bachelor's degree in Accounting from King Saud University, a Certified Public Accountant (CPA) and from the Saudi Organization for Auditors Accountants (SOCPA).

Current Executive Positions

- Member of the Audit Committee at AME Company for Medical Supplies – JSC
- Member of the Audit Committee at Sadara Capital

Nawaf bin Khalid Al-Aidan



Position

Audit Committee Member

About the member

A Certified Public Accountant (SOCPA), he possesses over seven years of distinguished professional experience in internal audit and financial control. Currently serving as the Internal Audit Manager at Center3, a subsidiary of STC Group, he has diverse expertise in investment auditing, operational auditing, and auditing financial departments and financial statements. He also has experience in quality assurance and improvement programs related to internal audit management, in addition to participating in advanced leadership and development programs such as the Corporate Leadership Program at IE Business School.

Academic Qualification

Mr. Nawaf bin Khalid Al-Aidan holds a Bachelor's degree in Accounting from King Saud University, a Certified Public Accountant (CPA) and from the Saudi Organization for Auditors Accountants (SOCPA).

Current Executive Positions

- Member of the Audit Committee at AME Company for Medical Supplies – JSC

Audit Committee's Competence

The Audit Committee is responsible for monitoring the company's operations, verifying the accuracy and integrity of financial reports and statements, and assessing the effectiveness of internal control systems. The Audit Committee is accountable to the Board of Directors for its work. The Audit Committee may request the Board to convene the company's General Assembly if the Board obstructs its work. This does not affect the Board's responsibility for the Committee's work, the powers or authorities delegated to it, or the procedures established by the Board regarding the Committee's mandate, term, powers, and oversight. The Committee must transparently inform the Board of its findings and decisions. The Committee's responsibilities include, in particular, the following:

Financial Reporting

1. Review the company's financial statements and provide an opinion before their presentation to the Board of Directors.
2. Review any significant or unusual matters included in the financial reports.
3. Thoroughly examine any issues raised by the company's Chief Financial Officer, their designee, the company's compliance officer, or the auditor.
4. Verify the accounting estimates in material matters presented in the financial reports.
5. Review the company's accounting policies and provide an opinion and recommendation to the Board of Directors regarding them.

Internal Audit

1. Review internal audit reports and follow up on the implementation of corrective actions in light of the observations contained therein.
2. Monitor and supervise the performance and activities of the internal auditor or the company's internal audit department, if one exists, to verify the availability of necessary resources and their effectiveness in performing the assigned tasks and duties. If the company does not have an internal auditor, the committee must submit a recommendation to the board of directors regarding the need to appoint one, or to appoint a professional firm to perform the internal audit functions.
3. Recommend to the board of directors the appointment of the head of the internal audit department or the internal auditor, and propose their remuneration, or the appointment of a professional firm to perform the internal audit functions, and propose their fees and scope of work.

External Audit

1. Recommending to the Board of Directors the nomination and dismissal of auditors, determining their fees, and evaluating their performance, after verifying their independence and reviewing their scope of work and contractual terms.
2. Reviewing the company's auditor's plan and work, verifying that they have not performed technical or administrative tasks outside the scope of the audit, and providing an opinion on this matter.
3. Responding to inquiries from the company's auditor.
4. Reviewing the auditor's report and observations on the financial statements and following up on the actions taken in response.

02 Nominations and Remuneration Committee

In accordance with the powers granted to the Board of Directors of “AME” Company for Medical Supplies, and stipulated in the Company’s bylaws, the Company’s governance guide and the authority matrix, the Company’s Board of Directors decided 032025/08/G. to approve the formation and commencement of the work of the Nominations and Remuneration Committee of the Board of Directors, starting from July 31, 2025G for a duration of 4 years up to the end of the current term of the Board of Directors, as follows

Latifa bint Abdul Rahman Al-Hudaib



Position

Chairman of the Nominations and Remuneration Committee

Please review the biographies of board members

Faisal bin Mohammad Al-Omran



Position

Member of the Nominations and Remuneration Committee

Please review the biographies of board members

Abdulaziz bin Saleh Aloamir



Position

Member of the Nominations and Remuneration Committee

Please review the biographies of board members

Competence of the Nominations and Remuneration Committee Members

The Nominations and Remuneration Committee is responsible for supervising and recommending to the Board of Directors nominations for Board membership in accordance with the approved policies and standards and developing clear policies for compensation and remuneration for members of the Board of Directors, Board committees, and senior executives, and reviewing them periodically. The committee’s Competencies include:

1. Recommending to the Board of Directors to nominate members and re-nominate them in accordance with approved policies and standards.
2. Proposing clear policies and standards for membership of the Board of Directors and executive management.
3. Preparing a clear policy for the remuneration of members of the Board of Directors, the Board committees, and Executive Management, and submitting it to the Board of Directors for consideration in preparation for approval by the General Assembly, provided that this policy takes into account following the standards related to performance, disclosing them, and verifying their implementation.
4. Periodically reviewing the remuneration policy and evaluating its effectiveness in achieving the desired goals.
5. Recommending to the Board of Directors the remuneration of the members of the Board of Directors, its committees, and senior executives of the company in accordance with the approved policy.
6. Preparing a description of the capabilities and qualifications required for membership in the Board of Directors and filling executive management positions.
7. Determining the time that the member must allocate to the work of the Board of Directors.
8. Annual review of the necessary needs of skills or experience appropriate to the membership of the board of directors and the functions of executive management.
9. Reviewing the structure of the Board of Directors and Executive Management and providing recommendations regarding the changes that can be made.
10. Verifying on an annual basis the independence of the independent members, and the absence of any conflict of interest if the member holds membership on the board of another company.
11. Develop job descriptions for executive members, non-executive members, independent members, and senior executives.

03

**Company's Main
Activities and
Segments**

Company activities



01

Pharmaceutical and herbal products wholesale

02

Medical devices, equipment, and supplies retail

03

Medical devices, equipment, and supplies wholesale

04

Cosmetics and soaps wholesale

05

Pharmacy activities

06

Medical devices and product stores

07

Cosmetics stores

08

Pharmaceutical stores

Exclusive agencies

01 TEOXANE

(TEOXANE) Laboratories was established in Geneva in 2003, by Madame Valérie Taupin, which specializes in the design and manufacturing of fillers and acid-based cosmeceuticals. As a result of our uncompromising commitment to innovation, quality, and patient satisfaction, (TEOXANE) Laboratories is now among the top hyaluronic acid-based filler manufacturers.

Teoxane produces (TEOSYAL®) range of products consists of unique dermal fillers with differing gel densities and unique properties making each one specific to treating different areas of the face and achieve different results, from prevention of fine lines and/or wrinkles to reshaping the facial features.

TEOSYAL RHA® products were developed in TEOXANE laboratories using a patented manufacturing process that enables them to meet the specific requirements of the mobile facial areas.

This technology preserves the natural characteristics of the hyaluronic acid molecules to obtain gels with high purity, close to the natural content of hyaluronic acid in the skin.



02 DEKA

For nearly 30 years, DEKA has been revolutionizing the world of medical technology with its innovative laser systems and treatments. Improving physician performance and patient well-being remains a core commitment of the company's founders, just as it has been since its inception.

In the highly competitive, high-tech market, DEKA focuses on continuous research and development to create unique products and technologies. The company prioritizes the needs of physicians and patients, leveraging its advanced in-house laboratories and close collaborations with leading research centers, medical facilities, and universities worldwide.

03 MAGELLAN



Magellan® is an Autologous Concentration System that delivers concentrated platelets and cells at the point of care.

The manufacturer, founded in the USA in 2007, specializes in developing innovative medical solutions aimed at improving surgical procedure outcomes.

Because each patient has unique biology and natural variations, the need for a customized solution for each individual case is essential.

Going beyond traditional standards of medical care, Magellan offers personalized biological therapy with its Autologous Cell Concentration System.

04 NABOTA



Founded in 1945, Daewoong Pharmaceuticals Co., Ltd. is a publicly traded South Korean pharmaceutical company engaged in the development, manufacturing, and marketing of medicines for both domestic and international markets.

With its strong sales and marketing departments, Daewoong ranks first in prescription drug sales in the South Korean market and currently markets 10 blockbuster pharmaceutical products.

Furthermore, the company has developed strong in-house capabilities in new drug development and expanded its regional and global partnerships with international partners.

As part of its vision to become a global healthcare company, Daewoong has expanded its international operations by establishing branches in various Asian countries, along with research centers in the USA, China, and India.

Currently, the company is constructing a new cGMP-compliant manufacturing facility to meet the needs of its global partners. A new botulinum toxin product, known as Nabota (code: DWP450004-), has been developed by Daewoong Pharmaceutical in Seoul, South Korea.

Which is a type A botulinum toxin derived from the same strain of Clostridium botulinum used in onabotulinumtoxinA.

In addition to therapeutic efficacy, the speed at which the effect appears may play an important role in patient satisfaction when used for facial aesthetics and skin rejuvenation.

05 EUROMI



Founded in 1990, (Euromi S.A) is a company specializing in the manufacture and distribution of medical, dermatological and aesthetic surgery equipment.

For many years, Euromi has provided comprehensive solutions in the field of cosmetic and reconstructive surgery. It is globally recognized for its unique and patented liposuction technology: Nutational Infrasonic Liposculpture (N.I.L.®).

This technology is used in a range of the company's liposuction products, trusted by thousands of professionals in the field, such as evamatic®, evasp®, and Cannulas.



06 ANTEAGE

The effectiveness of any skincare product depends heavily on the expertise behind it. AnteAGE® is managed by a elite group of leading researchers, scientists, and physicians who are among the top experts in their fields.

Our headquarters located in Irvine, California, where our team regularly publishes in scientific journals, is recognized for its groundbreaking results, and is consulted by Fortune 100 healthcare companies. AnteAGE® operates with the highest standards of safety and quality control to ensure that our products are effective and safe for our customers.

All stem cells derived from bone marrow, which are used to develop the biosignatures and growth factors in our products, are ethically sourced from healthy adult donors.

AnteAGE®'s mission is to deliver powerful anti-aging rejuvenating products based on supported scientific technologies.

AnteAGE® scientists have been pioneers in using human bone marrow stem cell technology in the fields of aesthetics and dermatology. The company is committed to harnessing the power of stem cell growth factors and cytokines to deliver skincare products that combine safety, effectiveness and luxury, and contribute to enhancing aesthetic wellness.



07 QuantifiCare

With over 25 years of experience in advanced medical imaging solutions, QuantifiCare is built on a solid scientific foundation. It is a spin-off company from the world-renowned French institute INRIA, which specializes in computer science and automated systems.

Through close collaboration with INRIA and joint research projects with leading centers worldwide, QuantifiCare has solidified its leadership position in the pharmaceutical, biotechnology, and aesthetic medicine industries.

QuantifiCare prides itself on being an imaging technology company that leverages its extensive history and expertise to innovate and deliver real value to its clients.

It was among the first companies to offer advanced image-assembly solutions for clinical experiments and was the first to develop a compact, portable 3D imaging system that enables standardized images with precise parameters.

08 Exosmart

Exosmart™ is a Class IIa CE-MDR-certified medical device revolutionizing regenerative medicine with its patented ultrafiltration technology.

Using a 15 kDa filter membrane, Exosmart™ converts 30 mL of plasma (derived from 60 mL of blood) into 6–7 mL of a concentrated therapeutic product containing up to 30 trillion exosomes per mL—136 times higher than reference standards.

Verification results conforming to MISEV2023 guidelines demonstrate exceptional purity of 93.2% of positive CD9 indices and a 47% increase in PDGF-bb growth factor. The concentrated product contains exosomes (30–150 nm), platelets (70–95% recovery rate), growth factors (VEGF, TGF- β , FGF), cytokines, and plasma proteins—all working synergistically to regulate inflammation, stimulate stem cells, promote angiogenesis, and accelerate tissue regeneration across a wide range of clinical applications.

With a proven safety profile (zero side effects in clinical trials) and a 100% treatment success rate, Exosmart™ transforms routine procedures into advanced regenerative therapy.

From orthopedics to cosmetic surgery, from wound care to surgical applications, this device delivers standardized and reproducible results, often achieved in just one session compared to multiple sessions with traditional methods.

09 MesoJet

MesoJet is an advanced cosmetic treatment device known for its non-surgical skin rejuvenation procedures.

The device utilizes jet stream technology to deliver a variety of active ingredients—such as serums, vitamins, and acids—deep into the skin without the need for needles.

This technology is based on a process called hydroporation, which allows for painless and effective transdermal nourishment.

MesoJet treatments are used to address a range of skin issues, including signs of aging, acne, hyperpigmentation, and skin damage, making them an ideal option for comprehensive, non-surgical skincare.

10 Mint Lift

MINT Lift® is a facial soft tissue stabilization system approved by the Korean Ministry of Food and Drug Safety for improving facial wrinkles.

Discover the effectiveness of MINT Lift®, which combines excellent lifting results with a high level of safety.

Unlike traditional threads produced using a cutting technique, MINT Lift® is manufactured using a patented compression molding technology, giving it significantly higher tensile strength and tissue stability, making it a superior option for non-surgical facelift treatments.






Information Technology

As part of developing its digital transformation journey, (AME) Company is making strenuous efforts to support and enable this path with professionalism and high efficiency, by working to complete the automation of the company's work procedures and systems, most notably the global (SAP) system, in addition to the advanced email system from Google (Gmail), which contains a strict system of high security and protection. In addition to other advanced systems related to computerizing and digitizing operations, such as following up on customer relations, all of which operate with advanced technical performance.

Meanwhile, the company seeks to devote a sustainable development methodology, in cooperation with the Human Resources Department, to build many procedures represented in developing the performance of the company's employees with high professionalism, enabling them to interact professionally in various work channels, and focusing them on projects related to digital transformation, which in turn expands the scope of work exerted to improve the business environment and professionalism, by adopting several effective systems and procedures to develop one of the most important aspects of digital transformation.



Human Resources Review

Distinctive operational work environment

AME Company For Medical Supplies is committed to implementing an ambitious strategy to build a distinguished operating environment and develop its strategy by supporting it with all services, solutions and facilities that make it a stable, integrated, competitive, and stimulating work environment, through which it attracts elite doctors, technicians, and specialized operational staff, retain them by developing their skills, abilities, experience, and enabling them to innovate and provide the best in their various tasks and job roles.

Successful localization strategy

The company continues to employ promising national talents, in response to the «Nitaqat» program launched by the Ministry of Human Resources Development, and based on our belief that investing in national talents can contribute to achieving the highest levels of creativity in work and purposeful thinking; by empowering creative young Saudi talents and giving them the full opportunity to develop their skills. The company's employment rates have been increased by attracting young Saudi talents; relying on them in the long and short term and developing plans to train them and develop their skills.

Year	Non-Saudi	Saudis	Total	Nationalization Percentage
2025	108	49	157	% 31.21
2024	79	46	125	% 39
2023	55	35	90	% 38.9
2022	44	22	66	% 33.33
2021	40	16	56	% 29

Distribution of employees according to main departments

	Department	Saudis	Non-Saudi
1	Executive Management	1	1
2	Finance Department	9	21
3	Legal Department	1	0
4	Governance, Compliance, and Risk Department	0	1
5	Internal Audit Department	0	1
6	Shared Services Department	4	7
7	Business Development and Marketing Department	2	1
8	Sales Department	30	56
9	Maintenance Department	0	11
10	Supply Chain Department	2	6
11	Regulatory Affairs Department	0	3

Attendance and Local and International Participation

AME Company sponsors or participates as an exhibitor in numerous high-profile conferences, events, and activities. These activities highlight its work and unwavering commitment to creating added value for the company by building trust and fostering strong relationships with all stakeholders, including customers, suppliers, and other business partners. The most important of these events and participations for 2025G are:

- Nabuta Event 2025G - Riyadh
- Saudi Dermatology Conference 2025G - Riyadh
- IMCAS Conference 2025G - Paris
- Biosome Event 2025G - Riyadh
- Jeddah Dermatology Conference 2025G - Jeddah
- Cadavar Azerbaijan Conference 2025G - Baku
- Saudi Society of Dermatology and Dermatologic Surgery Conference 2025G - Riyadh
- Cadavar Saudi Arabia Conference 2025G (1) - Riyadh
- First Scientific Academy of Trichology Conference and Exhibition 2025G - Riyadh
- Cadavar Istanbul Conference 2025G - Istanbul
- REACH Conference 2025G - Riyadh
- MIDAM Conference 2025G - Dubai
- AMWC 2025G - Dubai
- BDLA Conference 2025G - Bahrain
- Building Safe Injections Conference 2025G - Riyadh
- SAAM Conference 2025G - Riyadh
- Nabuta Advanced Course - Jeddah

A photograph of three men in a professional setting, overlaid with a semi-transparent blue filter. Two men on the left wear traditional Middle Eastern headwear (ghutra and agal) and light-colored thobes. The man on the right wears a dark Western business suit with a tie. They are all looking down at a document on a table, with one man pointing at it. A large white number '04' is centered on the left side of the image.

04

Challenges and Risks



In today's dynamic business environment, characterized by rapid economic and technological changes, AME Company For Medical Supplies prioritizes enhancing its ability to adapt to potential challenges and risks. The company adopts a proactive approach to risk management, aiming to protect its interests and ensure business sustainability by implementing global best practices in assessment and strategic planning.

The Board of Directors is committed to regularly reviewing and updating risk management policies to ensure their alignment with internal and external developments. Internal control systems are strengthened, and advanced methodologies for measuring risks and analyzing their impacts are adopted, enabling executive management to make decisions based on accurate data and sound strategies.

The company integrates risk management and governance systems across all operational levels, from daily activities to strategic decisions. Comprehensive response plans are developed to address various types of risks, whether related to organizational changes, economic fluctuations, or operational and technological challenges, with the goal of enhancing operational efficiency and resilience. The company's approach is based on continuous risk assessment, which includes monitoring influential variables, analyzing data, and implementing effective solutions to mitigate potential risks. This aligns with the company's commitment to promoting transparency and accountability, applying the highest standards of good governance, protecting the interests of shareholders and stakeholders, and enhancing the company's competitiveness in local and regional markets.




Strategic Risks

In light of the escalating challenges in the business environment, AME Company For Medical Supplies places great importance on monitoring and analyzing strategic risks that could affect its ability to achieve its long-term objectives. These risks include market volatility, rapid technological advancements, and changes in regulatory systems and legislation. This necessitates the adoption of flexible and proactive strategies to ensure business sustainability and foster future growth.

The company is committed to implementing a comprehensive strategic risk management framework, which includes identifying potential risks, assessing their impact, and developing appropriate strategies to address them. This process is integrated into the company's strategic planning system, contributing to business sustainability and the achievement of its approved goals.

The company also strives to enhance its risk awareness culture among its employees and provide the necessary training programs to ensure they understand their roles and responsibilities in risk management. Furthermore, the company develops effective response plans to address potential risks and ensure business continuity in the face of challenges. Through these efforts, the company seeks to strengthen its resilience and adaptability to changes, ensuring the achievement of its strategic objectives.



Risks related to the operation and unexpected business interruption

The Company relies on the effectiveness of its operational business to continue its operations, and any cessation or interruption of these operations for any reason, including but not limited to the issuance of new regulatory requirements or any failure affecting computer equipment or other matters that may lead to the interruption of these operations, will affect negatively and materially the Company's business, financial condition, and future prospects.



Risks of difficulty in recruiting people with experience in the health sector

The Company relies heavily on employees who have experience in the health sector to continue its activity and operations, especially those who work in the sales and maintenance departments, as they are required to be highly competent and fully familiar with the characteristics of medical products and devices in accordance with the standards required by customers. In the event that the Company is unable to employ qualified personnel and retain them to continue its operations, this will have a negative and material impact on the Company's business, the results of its operations, and its prospects. Therefore, the Company is keen to attract talent and work to develop their skills.



Risk of dependence on suppliers

The Company obtains medical products and instruments used primarily in the field of cosmetics and plastic surgery from international suppliers, all of whom are outside the Kingdom of Saudi Arabia. The Company may not be able to continue to rely on the suppliers it deals with, either because of a change in the existing relationships with them, or because of an increase in the cost of obtaining the products, or due to the supplier's inability to provide the Company with the required quantities of products according to the necessary quality at the appropriate time, or due to the supplier's desire to cancel or not renew the agreement. Therefore, the Company is keen on diversifying suppliers.



Risk of customer concentration

The Company's clients are specialized health clinics, hospitals, health centers, general dispensaries, and beauty centers. There is currently no concentration of revenues from clients as a result of the diversity of these clients. If the diversity of customers is not maintained in the future, this may lead to concentrating revenues on a limited number of customers. If a good and continuous relationship is not maintained with these major customers, or the Company fails to develop its relationship with new customers, this will have a significant negative impact on the Company's business, results of operations, and financial performance.



Risk related to the competitive environment

The Company works in the field of cosmetic medicine in the Kingdom, which is characterized by high competition, and therefore, if current or potential competitors offer competitive prices, conditions, or better solutions than those provided by the Company, the Company will not be able to compete with those companies, which will lead to a reduction in market share, thus negatively impacting its profits, results of operations and financial condition.



Risk of interest rate fluctuations

Interest rates may change depending on local or global economic, political, or regulatory variables, whether fixed or variable, due to the company's financing entities, and thus this will lead to an increase in the financing costs required by the company, which will have a negative impact on its business, results of operations, financial performance, and profitability.



Risk of growth opportunities

The Company's ability to develop its business depends on the level of competition in the market, the availability of material and human resources, the ability of its management team, and legal systems among others. There is no guarantee that it will maintain a level of continuous growth, as the Company may face difficulties in expanding its activity, developing its market share, and increasing its sales. Therefore, if the Company is unable to manage its growth positively, its ability to develop its activity and increase its market share, or maintain it and increase it, may affect its profits and enhance returns to its shareholders, which will have a negative and material impact on the Company's financial performance, its financial condition and its prospects.



Risks related to the Company's share

Future distribution of dividends depends on several factors including, but not limited to, future profits, financial condition, capital requirements, the Company's distributable reserves, general economic conditions, analysis of investment opportunities and needs, and other relevant factors which the Board of Directors may consider important from time to time, on the basis of which the Board of Directors will decide whether or not to submit any recommendation to the General Assembly of Shareholders to distribute dividends in the future. The Company provides no guarantee whatsoever that the Board of Directors will recommend the distribution of dividends or that the Board of Directors' recommendation to distribute any dividends will be approved by shareholders at the General Assembly meetings, nor does the Company provide any guarantee regarding the amount of amounts that will be paid as dividends in any given year.

05

**Financial
Results for the
Year 2025G**

Auditor's Report - Ernst & Young Professional Services

Report on the Audit of the Financial Statements

Opinion

We have audited the financial statements of AME Company for Medical Supplies (a Saudi Joint Stock Company) («the Company»), comprising the statement of financial position as of December 31, 2025, the statement of profit or loss and other comprehensive income, the statement of changes in equity, the statement of cash flows for the year then ended, and the notes to the financial statements, including material accounting policy information.

In our opinion, the accompanying financial statements present fairly, in all material respects, the company's financial position as of December 31, 2025, and its financial performance and cash flows for the year then ended, in accordance with International Financial Reporting Standards as adopted in the Kingdom of Saudi Arabia, and other standards and pronouncements issued by SOCPA.

Basis for Opinion

Our audit was conducted in accordance with International Standards on Auditing as adopted in the Kingdom of Saudi Arabia. Our responsibilities under those standards are set out in the Auditor's Responsibilities section of our report. We are independent of the company in accordance with the International Code of Conduct for Professional Accountants (including the International Independence Standards) adopted in the Kingdom of Saudi Arabia, as applicable to the audit of the financial statements of entities of public interest, and we have fulfilled our other ethical responsibilities in accordance with that Code. We believe that the audit evidence we obtained is sufficient and appropriate to provide a basis for our opinion.

Key Audit Matters

Key audit matters are those which, in our professional judgment, were of significant importance in our audit of the current period's financial statements. These matters were addressed in the context of our audit of the financial statements as a whole and in forming the auditor's opinion on them. We do not provide a separate opinion on these matters. A description of each key audit matter and how it was addressed within that context is provided below.

We have fulfilled our responsibilities as described in the Auditor's Responsibilities section of our report, including those relating to these matters. Accordingly, our audit included procedures designed to address our assessment of the risk of material misstatements in the financial statements. The results of our audit procedures, including the actions taken to address the matters below, provide a basis for our audit's opinion on the accompanying financial statements.



Key Audi Matters	How We Addressed This During Our Audit
------------------	--

As of December 31, 2025, the total value of Trade Receivables and Installment Sales Receivables amounted to SAR 168.3 million (2024: SAR 134 million), against which an expected credit loss provision of SAR 28 million (2024: SAR 11.8 million) was provisioned.

The company's management applied a simplified expected credit loss model to determine the expected credit loss provision for Trade Receivables and Installment Sales Receivables as of December 31, 2025. The expected credit loss model incorporates various assumptions, macroeconomic factors, and a audit of historical trends related to the company's Trade Receivables and Installment Sales Receivables collection experiences, in accordance with the requirements of IFRS 9 - Financial Instruments.

We have deemed this a major audit matter due to the provisions and estimates involved in applying the expected credit loss model and its impact on accounts receivable balances for installment sales and trade receivables.

Please refer to Notes 2 and 3 for the accounting estimates and policies, respectively, and Notes 11 and 12 to the financial statements.

Other Matter

The Company's financial statements for the year ended December 31, 2024, were audited by another auditor who issued an unmodified opinion on those financial statements on March 26, 2025 (corresponding to Ramadan 26, 1446H).

The audit procedures we performed included, among other things:

- We assessed the company's accounting policy regarding the provision for expected credit losses to ensure compliance with the requirements of IFRS 9.
- We gained an understanding of management's assessment regarding the impairment of trade receivables, installment sales receivables, and the provision for expected credit losses.
- We engaged our internal experts to assess the reasonableness of the significant judgments, estimates, and assumptions made by management regarding the company's assessment of the likelihood of default, the inclusion of forward-looking information, and the default loss standard used in the expected credit loss model.
- We tested the accuracy of the aging classification of trade receivables and installment sales receivables extracted from the accounting system used to prepare the expected credit loss model as of December 31, 2025.
- We tested the accounting accuracy of the expected credit loss model.
- We have assessed the adequacy and appropriateness of the relevant disclosures in the accompanying financial statements.

Other Information in the Company's 2025 Annual Report

Other information includes the information contained in the Company's 2025 Annual Report, excluding the financial statements and the auditor's report. Management is responsible for the other information in its annual report. The Company's 2025 Annual Report is expected to be available to us after the date of the auditor's report.

Our opinion on the financial statements does not cover this other information, and we will not express any affirmative action regarding it.

Other Information Contained in the Company's Annual Report for 2025 (Continued)

Regarding our audit of the financial statements, our responsibility is to read the other information referred to above when available. In doing so, we will consider whether the other information is materially inconsistent with the financial statements, with the knowledge we gained during the audit, or otherwise appears to be materially misrepresented.

When we audit the Company's Annual Report for 2025, if we find a material misrepresentation, we are required to report it to the responsible authorities.

Management and corporate officers Responsibilities Regarding Financial Statements

Management is responsible for preparing and fairly presenting the financial statements in accordance with International Financial Reporting Standards (IFRS) as adopted in the Kingdom of Saudi Arabia, other standards and pronouncements issued by (SOCPA), the provisions of the applicable Companies Law and the Company's Articles of Association, and for implementing the internal controls that management deems necessary to prepare financial statements free from material misrepresentation resulting from fraud or error. When preparing financial statements, management is responsible for assessing the company's ability to continue as a going concern and for disclosing, as appropriate, matters relevant to the going concern principle and applying the going concern principle in accounting, unless management intends to liquidate the company or cease operations, or there is no other suitable option.

Those responsible for governance, namely the audit committee, are responsible for overseeing the company's financial reporting process.

Auditor's Responsibilities Regarding the Audit of Financial Statements

Our objectives are to obtain reasonable assurance as to whether the financial statements as a whole are free from material misstatement due to fraud or error, and to issue an auditor's report containing our opinion. Reasonable assurance is a high level of assurance, but it is not a guarantee that an audit performed in accordance with International Standards on Auditing (ISAs) as adopted in the Kingdom of Saudi Arabia will always uncover material misstatement. Misstatements can arise from fraud or error and are material, individually or in combination, if it is reasonably foreseeable that they will affect the economic decisions made by users based on those financial statements.

As part of the audit in accordance with International Standards on Auditing (ISAs) adopted in the Kingdom of Saudi Arabia, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- 01** Identify and assess the risk of material misstatements in the financial statements, whether due to fraud or error, and design and implement audit procedures to address those risks and obtain sufficient and appropriate audit evidence to provide a basis for our opinion. The risk of failing to detect a material misstatement due to fraud is higher than the risk due to error, as fraud may involve collusion, forgery, willful omission, misrepresentation, or violation of internal control procedures.
- 02** Gain an understanding of the internal controls relevant to the audit, in order to design appropriate audit procedures in accordance with the circumstances, not to express an opinion on the effectiveness of the company's internal controls.
- 03** Evaluate the appropriateness of the accounting policies used and the reasonableness of the accounting estimates and related disclosures made by management.

Auditor's Responsibilities Regarding the Audit of Financial Statements (continued)

- 01** To determine the appropriateness of management's application of the going concern principle in accounting and, based on the audit evidence obtained, whether there is a material uncertainty regarding events or circumstances that may cast significant doubt on the company's ability to continue as a going concern. If we find a material uncertainty, we must draw attention in our report to the relevant disclosures in the financial statements, or, if those disclosures are inadequate, modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our audit report. However, future events or circumstances may cause the company to cease to be a going concern.
- 02** To assess the overall presentation, structure, and content of the financial statements, including disclosures, and whether the financial statements present the transactions and events they represent in a manner that provides a fair presentation.

We inform, among others, those responsible for governance of the scope and planned timing of the audit and any significant audit findings, including any significant deficiencies in internal controls identified during our audit.

We also provide our auditors with a statement that we have complied with the relevant ethical requirements relating to independence, and we inform them of all relationships and other matters that may reasonably be believed to affect our independence. Where appropriate, we also inform them of the actions taken to eliminate threats or the preventive measures implemented.

Of the matters reported to those responsible for governance, we identify those that were of paramount importance during the review of the financial statements for the current period, and these constitute the principal matters of the audit. We disclose these matters in our report unless a regulation or law prohibits public disclosure, or—in very rare circumstances—we believe that the adverse consequences of reporting them reasonably outweigh the public interest in such disclosure.

Financial performance

Geographic analysis of the total revenues of the Company and its subsidiaries

The Company's business and revenues were concentrated in the Central region, and the Western region, and the Eastern Region as shown in the following table:

Total	Eastern Region	Central Region	Western Region	Total revenue	Year
2025	304,963,333	107,572,207	162,932,702	34,458,424	304,963,333

Statement of assets, liabilities, and shareholders' equity for the last five financial years (SAR' 000)

Description	2021	2022	2023	2024	2025	Change between 2024-2025-
Current Assets	130,860	151,811	183,951	221,984	268,060	20.76%
Non-current assets	3,029	2,552	6,269	7,425	6,449	(13.14%)
Total assets	133,889	154,363	190,220	229,409	274,509	19.66%
Current liabilities	31,907	37,429	52,162	58,873	81,655	38.70%
Non-current liabilities	8,567	9,584	10,888	11,707	13,670	16.77%
Total liabilities	40,474	47,013	63,050	70,580	95,324	35.06%
Paid-up Capital	70,000	70,000	70,000	70,000	70,000	0%
Issue premium	-	-	-	-	--	0%
Statutory reserves and retained earnings	23,414	37,350	57,169	88,829	109,185	22.92%
Total equity	93,414	107,350	127,169	158,829	179,185	12.82%

Statement of income for the last five fiscal years (SAR'000)

Description	2021	2022	2023	2024	2025	Change between 2025-2024
Revenues	151,386	193,170	220,014	248,351	304,963	22.80%
Cost of Revenue	(81,841)	(102,888)	(124,566)	(146,191)	(176,476)	20.72%
Gross profit	69,545	90,282	95,448	102,160	128,487	25.77%
Net profit	18,843	26,185	33,809	45,648	34,356	(24.74%)

Substantial differences in operating results from the results of the previous year (SAR' 000)

Description	2024	2025	Changes	Percentage of Change
Revenue	22.80%	56,612	304,963	248,351
Government grants and subsidies	--	--	--	--
Cost of revenue	20.72%	(30,285)	(176,476)	(146,191)
Gross profit	25.77%	26,327	128,487	102,160
Advertising and publicity expenses	8.28%	(2,943)	(38,490)	(35,547)
General and administrative expenses	44.68%	(10,355)	(33,533)	(23,178)
Reversal of losses)) Impairment losses on receivables	(1.045.67%)	(17,996)	(16,275)	1,721
Other income	(41.45%)	(1,921)	2,713	4,634
Operating profit	(13.83%)	(6,888)	42,902	49,790
Financing costs, net	(1550.59%)	(3,923)	(4,176)	253
Zakat	(19.94%)	(926)	(3,717)	(4,643)
Net profit	(24.74%)	(11,292)	34,356	45,648

Statutory Payments to Government agencies (SAR '000)

Description	Paid	Due until the end of the annual financial period and not paid	A Brief Description	Description
Zakat	4,151	7,566	Zakat provision for the year 2025 with an opening balance	
Value added tax	--	2,761	Company's VAT receivables	
General Organization for Social Insurance	1,373			
Visa and passport costs	216			
Labor office fees	1,053			
Total				

06

Dividends Distribution

Dividends Distribution



Article 36 of the Company's Articles of Association (Reserve Formation)

- 01 The Ordinary General Assembly - when determining the share of shares in net profits - may decide to form reserves, to the extent that serves the interest of the company or ensures the distribution of fixed profits - as much as possible - to shareholders. The aforementioned association may also deduct amounts from the net profits to achieve social purposes for the company's employees.
- 02 The General Assembly determines the percentage that must be distributed to shareholders from the net profits after deducting reserves, if any

Article 32 of the Company's Articles of Association (Dividend Entitlement)

A shareholder is entitled to his share in the profits in accordance with the decision of the General Assembly issued in this regard. The decision indicates the due date and the date of distribution. Eligibility for the dividends is to the owners of shares registered in the shareholders' register at the end of the day specified for entitlement. The Board of Directors must implement the General Assembly's decision regarding the distribution of profits to shareholders.

Percentages and the totals of profits distributed to Shareholders during the various periods of the fiscal year ending on 31 December 2025:

Percentage of Distributed Profits	
Date of distribution	11/06/2025
Percentages	20%
Total	SAR 14,000,000

Audit Committee Report



Committee opinion

Based on the periodic reports submitted to the Audit Committee during 2025, the Committee conducted a comprehensive evaluation of the Company's internal control systems. The Committee is of the opinion that the internal control environment still requires substantial improvements and continuous development to ensure the highest levels of efficiency and effectiveness in risk management and control mechanisms. This is primarily due to the absence of core internal audit activities during the year.

In response, the Committee instructed the Internal Audit Department to develop a risk-based internal audit plan for 2026, which has since been approved. The Committee recognizes that activating the internal audit function will enhance the capacity to examine control measures and assess their efficiency and effectiveness.

Regarding the financial reporting system, the Committee believes that the financial reports are reliable, ensure proper disclosure of information, and comply with the International Financial Reporting Standards (IFRS) as well as other standards and pronouncements endorsed by the Saudi Organization for Chartered and Professional Accountants (SOCPA). The financial reports are free from any material deficiencies that might hinder the achievement of the Company's objectives.

In this context, the Committee reaffirms its commitment to exercising its oversight role with full independence, in accordance with the highest professional standards. It remains dedicated to strengthening governance and control mechanisms to bolster shareholder confidence and ensure the sustainability of financial and operational performance. Furthermore, the Committee will continue to provide strategic recommendations and monitor their implementation to add real value to the Company and its shareholders.

07

Corporate Governance

AME



Board of Directors Meetings Record

The Board of Directors of AME for Medical Supplies Company held a total of five meetings during 2025G. Details of these meetings, including dates and attendance percentages, are provided below.

Details of the Board of Directors meetings – First term (from 01/01/2025G to 30/07/2025G):

Member Name	Position	Meeting dated		Percentage of Total attendance
		23/03/2025	26/05/2025	
Mr. Ammar Ahmed Saleh Shatta	Chairman of the Board	Attended	Attended	100%
Mr. Ahmed Saud Hamza Ghouth	Deputy Chairman of the Board	Attended	Attended	100%
Dr. Ali Mohammed Deeb Ali Eid	Board Member / Managing Director	Attended	Attended	100%
Mr. Hisham Omar Ali Baroom	Board Member	Attended	Attended	100%
Mr. Adnan Abdullah Al-Olayan	Board Member	Attended	Attended	100%

Details of the Board of Directors meetings – Second term (from 31-07-2025G to 31-12-2025G)

Member Name	Position	Meeting dated			Percentage of Total attendance
		03/08/2025	08/10/2025	13/11/2025	
Mr .Faisal bin Mohammad Al-Omran	Chairman of the Board	Attended		Attended	100%
Mr. Abdulaziz bin Saleh Aloamir	Deputy Chairman of the Board	Attended		Attended	100%
Dr. Ali Mohammed Deeb Ali Eid	Board Member / Managing Director	Attended		Attended	100%
Mrs. Latifa bint Abdul Rahman Al-Hudaib	Board Member	Attended		Attended	100%
Khalid bin Saeed Al-Safri	Board Member	Attended		Attended	100%

Audit Committee Meeting Record

The audit committee of AME for Medical Supplies Company held a total of seventeen meetings during the year 2025G. The details of these meetings are listed below in terms of the dates they were held and the attendance rates.

Details of the Audit Committee meetings – Second term (from 01/01/2025G to 30/07/2025G):

Meeting date	Committee Member			Percentage of Total attendance
	(Member Name (position)			
	Mohammed bin Saleh Al Zahrani Chairman of the Committee	Adnan bin Abdullah Al-Olayan Committee Member	Hafez Farouk Suleiman Al-Atawneh Committee Member	
02/02/2025	✓	✓	✓	100%
19/03/2025	✓	✓	✓	100%
20/05/2025	✓	✓	✓	100%
15/07/2025	✓	✓	✓	100%

:(Details of the Audit Committee meetings – Third term (from 31/07/2025G to 31/12/2025G

Meeting date	Committee Member			Percentage of Total attendance
	Member Name (position)			
	Saleh bin Abdullah Al Qraisha Chairman of the Committee	Hattan bin Abdul Wahab Al-Qahtani Committee Member	Mr. Nawaf bin Khalid Al-Aidan Committee Member	
10/08/2025	✓	✓	✓	٪100
14/08/2025	✓	✓	✓	٪100
19/08/2025	✓	✓	✓	٪100
19/08/2025	✓	✓	✓	٪100
27/08/2025	✓	✓	✓	٪100
17/09/2025	✓	✓	✓	٪100
05/10/2025	✓	✓	✓	٪100
16/10/2025	✗	✓	✓	٪66.67
12/11/2025	✓	✗	✓	٪66.67
20/11/2025	✓	✓	✓	٪100
23/11/2025	✓	✓	✓	٪100
04/12/2025	✓	✓	✓	٪100
11/12/2025	✓	✓	✓	٪100

Nominations and Remuneration Committee Meetings Record

The Nominations and Remuneration Committee of AME for Medical Supplies Company held a total of five meetings during the year 2025G. The details of these meetings are listed below in terms of the dates they were held and the attendance rates.

Details of the Nominations and Remuneration Committee meetings
First term (from 01/01/2025G to 30/07/2025G):

Meeting date	Committee member			Percentage of total attendance
	Member Name (position)			
	Adnan bin Abdullah Al-Olayan Chairman of the Committee	Khaled bin Fahd Al-Hazeem Committee member	Hamad bin Hamdan 'Al Sarie Committee member	
13/02/2025	✓	✓	✓	100%
30/04/2025	✓	✓	✓	100%
30/06/2025	✓	✓	✓	100%

Details of the Nominations and Remuneration Committee meetings
Second term (from 31/07/2025G to 31/12/2025G):

Meeting date	Committee member			Percentage of total attendance
	Member Name (position)			
	Latifa bint Abdul Rahman Al-Hudaib Chairman of the Committee	Faisal bin Mohammad Al-Omran Committee member	Abdulaziz bin Saleh Aloamir Committee member	
08/09/2025	✓	✓	✓	100%
13/11/2025	✓	✓	✓	100%



General Assembly of Shareholders meetings and resolutions register



We would like to clarify that during the fiscal year 2025G, an Extraordinary General Assembly was held on May 25, 2025G, and an Ordinary General Assembly was held on July 27, 2025G, both in person at the company's headquarters in Jeddah and via modern technology. The details of the meetings and the names of the attending Board members are as follows:

1st Extraordinary General Assembly (May 25, 2025G) First Meeting

Member Name	Ordinary General Assembly meetings during 2024G
	First Meeting
Ammar bin Ahmed Shata	✓
Ahmed bin Saud Ghouth	✓
Hisham bin Omar Baroum	✓
Ali Mohammed Deeb Ali Eid	✓
Adnan Abdullah Mohammed Al-Olayan	✓

Resolutions of the Extraordinary General Assembly:

#	Item
1	The amendment to Article (12) of the Company's Articles of Association, concerning the Board of Directors' Management, was rejected.
2	The amendment to Article Nineteen of the Company's Articles of Association, concerning the quorum for Board of Directors meetings, was approved.
3	The Board of Directors' report for the fiscal year ending December 31, 2024, was reviewed and discussed.
4	The financial statements for the fiscal year ending December 31, 2024, were reviewed and discussed.
5	The auditor report for the fiscal year ending December 31, 2024, was approved after discussion.

#	Item
6	The termination of the contract with the current Company auditor was approved, due to the expiration of the maximum period permitted by law, as stipulated in Article (3) of the Implementing Regulations of the Companies Law issued by the Capital Market Authority pertaining to listed joint-stock companies.
7	The appointment of Ernst & Young as the Company's auditor from among the candidates, based on the recommendation of the Audit Committee, was approved. This is to examine, review, and audit the financial statements for the first, second, and third quarters and the full year of fiscal year 2025G. and for the first, second, and third quarters and the full year of fiscal years 2026 and 2027, and to determine the fees as follows: - For the year 2025: SAR 711,000 - For the year 2026: SAR 747,000 - For the year 2027: SAR 786,000
8	Approval of the discharge of the Board of Directors for the fiscal year 2024
9	Approval of the termination of the current Board of Directors' term Prematurely, effective July 30, 2025
10	Approval of the Board of Directors' recommendation to distribute dividends of SAR 14,000,000 (fourteen million riyals) to shareholders for the fiscal year ending December 31, 2024, at a rate of SAR 2 (two riyals) per share, representing 20% of the share capital. Eligibility for dividends will be for shareholders who own shares at the close of trading on the day of the General Assembly meeting and are registered in the company's shareholder register at the Securities Depository Center Company (Edaa) at the end of the second trading day following the entitlement date. Dividend payments will commence on June 11, 2025G. with transfers to the accounts linked to the portfolios of eligible shareholders.
11	Approval of the payment of SAR 660,000 as remuneration to the members of the Board of Directors for the fiscal year ending December 31, 2024.
12	Approval of the amendment to the Board of Directors' Remuneration Policy.
13	Approval of the policy for the criteria and procedures for the Board of Directors nomination.

2nd The Ordinary General Assembly (27/07/2025G) First Meeting

Member Name	Ordinary General Assembly meetings during 2024G	
	First Meeting	
Ammar bin Ahmed Shata	✓	
Ahmed bin Saud Ghouth	✓	
Hisham bin Omar Baroum	Did Not Attend	
Ali Mohammed Deeb Ali Eid	✓	
Adnan Abdullah Mohammed Al-Olayan	✓	

Resolutions of the Ordinary General Assembly:

#	Item
1	The election of the Board of Directors members from among the candidates for the upcoming term, which begins on 31/07/2025G and lasts for four years, ending on 30/07/2029, was conducted by vote. The elected members are: 1. Dr. Ali Mohammed Deeb Ali Eid 2. Mr. Faisal bin Mohammad Al-Omran 3. Mr. Abdulaziz bin Saleh Aloamir 4. Mrs. Latifa bint Abdul Rahman Al-Hudaib 5. Mr. Khalid bin Saeed Al-Safri



Remuneration of the Board of Directors

Board of Directors' Remuneration (First Term from 01/01/2025G to 30/07/2025G)

Member Name	Specific Amount	Allowance for Attending Board Meetings	Fixed Remuneration				Variable Remuneration						Expense allowance			
			Total Allowance for Attending Committees Meetings	In-Kind Benefits	Remunerations for Technical, Managerial and Consultative Work	Remunerations of the Chairman, Managing Director or Secretary, if a member	Total	Percentage of Profits	Periodic Remuneration	Short-Term Incentive Plans	Long-Term Incentive Plans	Granted Shares (value (is entered		Granted Shares (value	End-of-Service Indemnity	total summation
First: Independent Members																
Ammar bin Ahmed Shata	30,000	5,000	-	-	-	-	35,000	-	-	-	-	-	-	-	35,000	-
Adnan bin Abdullah Al-Olayan	25,000	5,000	100,000	-	-	-	130,000	-	-	-	-	-	-	-	130,000	-
Ahmed bin Saud Ghouth	25,000	5,000	-	-	-	-	30,000	-	-	-	-	-	-	-	30,000	-
Hisham bin Omar Baroum	25,000	5,000	-	-	-	-	30,000	-	-	-	-	-	-	-	30,000	-
Second: Non-Executive Members																
Third: Executive members																
Ali Mohammed Deeb Ali Eid	25,000	5,000	-	-	700,000	-	730,000	-	-	-	-	-	-	-	730,000	-
Total	130,000	25,000	100,000		700,000		955,000								955,000	

Board of Directors' Remuneration (Second Term from 31/07/2025G to 31/12/2025G)

Member Name	Specific Amount	Allowance for Attending Board Meetings	Fixed Remuneration					Variable Remuneration						Expense allowance			
			Total Allowance for Attending Committees Meetings	In-Kind Benefits	Remunerations for Technical, Managerial and Consultative Work	Remunerations of the Chairman, Managing Director or Secretary, if a member	Total	Percentage of Profits	Periodic Remuneration	Short-Term Incentive Plans	Long-Term Incentive Plans	Granted Shares (value (is entered	Granted Shares (value		End-of-Service Indemnity	total summation	
First: Independent Members																	
Latifa bint Abdul Rahman Al-Hudaib	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Khalid bin Saeed Al-Safri	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Second: Non-Executive Members																	
Faisal bin Mohammad Al-Omran	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Abdulaziz bin Saleh Aloamir	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Third: Executive members																	
Ali Mohammed Deeb Ali Eid	-	-	-	-	500,000	-	500,000	-	-	-	-	-	-	-	-	500,000	-
Total					500,000											500,000	

Remuneration of Board Committees

Remuneration of members of the Audit Committee (Second term from 01/01/2025G to 30/07/2025G)

Member Name	Fixed Remuneration	Attendance of Meetings Allowance	Total
Mohammed bin Saleh Al-Zahrani	37,500	10,000	47,500
Adnan Abdullah Al-Olayan	40,000	10,000	50,000
Hafez Farouk Suleaiman Al-Atawneh	40,000	10,000	50,000
Total	117,500	30,000	147,500

Remuneration of members of the Audit Committee (Third term from 31/07/2025G to 31/12/2025G)

Member Name	Fixed Remuneration	Attendance of Meetings Allowance	Total
Saleh bin Abdullah Al Qraisha	-	-	-
Hattan bin Abdul Wahab Al-Qahtani	-	-	-
Nawaf bin Khalid Al-Aidan	-	-	-
Total	-	-	-

Note: No bonuses or attendance allowances were received for the third session during the year 2025G.

Remuneration for members of the Nominations and Remuneration Committee (First term from 01/01/2025G to 30/07/2025G)

Member Name	Fixed Remuneration	Attendance of Meetings Allowance	Total
Adnan Abdullah Al-Olayan	40,000	5,000	45,000
Khaled bin Fahd Al-Hazeem	75,000	5,000	80,000
'Hamad bin Hamdan Al Sarie	75,000	5,000	80,000
Total	190,000	15,000	205,000

Remuneration for members of the Nominations and Remuneration Committee (Third term from 31/07/2025G to 31/12/2025G)

Member Name	Fixed Remuneration	Attendance of Meetings Allowance	Total
Latifa bint Abdul Rahman Al-Hudaib	-	-	-
Faisal bin Mohammad Al-Omran	-	-	-
Abdulaziz bin Saleh Aloamir	-	-	-
Total	-	-	-

Note: No bonuses or attendance allowances were received for the third session during the year 2025G.

Remuneration and Compensation of Senior Executives, including Managing Director, CEO and CFO

Senior executive jobs	Variable Remuneration				Fixed Remuneration						End-of-Service	Total compensation for executives on the board, if any	Total
	salaries	In-Kind Benefits	Allowances	Total	Total	Granted shares	Long-term incentive plans	Short-term incentive plans	Dividends	Regular remuneration			
Managing Director	5,805,802	30,000	-	5,775,802	-	-	-	-	1,736,249	4,039,553	-	890,608	3,148,925

Relationship between the remuneration granted and the applicable Remuneration policy

Based on the specific remuneration policy of the Board of Directors, its committees, and the executive management, which was previously mentioned in this report, and in light of the remuneration paid to the members of the board, committees, and executive management, The remuneration is found to be consistent with the approved policy of the Company without any material deviation from the aforementioned policy.

Company Ownership (Substantial Shareholders - Board Members, their spouses, and minor children)

Substantial Shareholders and change in their ownership interests

Shareholder Name	Beginning of 2025G		End of 2025G		Changes	
	Number of Shares	Ownership Percentage	Number of Shares	Ownership Percentage	Share changes	Percentage
Ali Mohammed Deeb Ali Eid	1,051,532	15%	1,052,000	15%	468	-

Percentage of shares ownership and its change during the year 2025G for members of the Board of Directors, senior executives, their spouses, and minor children:

Shareholder Name	Beginning of 2025G		End of 2025G		Changes	
	Number of Shares	Ownership Percentage	Number of Shares	Ownership Percentage	Number of Shares	Ownership Percentage
Ali Mohammed Deeb Ali Eid	1,051,532	15%	1,052,000	15%	468	0%
Mawadda bint Ali bin Muhammad Deeb Eid	189,000	2.7%	189,000	2.7%	-	-
Talia bint Ali bin Muhammad Deeb Eid	188,999	2.69%	188,999	2.69%	-	-
Faisal bin Mohammad Al-Omran	19,708	0.28%	35,000	0.5%	15,292	0.22%
Abdulaziz bin Saleh Aloamir	0	0%	1,038	0.014%	1,038	0.014%
Latifa bint Abdul Rahman Al-Hudaib	0	0%	1,003	0.014%	1,003	0.014%

Table of Shareholders' Register Requests

The shareholders' register was requested from the Depository Center Company (Edaa) 18 times during the year 2025G. The following is a statement showing the dates of these requests and the reasons for each of them:

N	Register type	Request date	Reasons for request
1	Quantities –identity level (A)	2025/02/05	Other – Internal Procedures
2	Quantities –identity level (A)	2025/02/17	Other – Internal Procedures
3	Quantities –identity level (A)	2025/03/02	Other – Internal Procedures
4	Quantities –identity level (A)	2025/03/26	Other – Internal Procedures
5	Quantities –identity level (A)	2025/04/22	Other – Internal Procedures
6	Quantities –identity level (A)	2025/05/18	Other – Internal Procedures
7	Quantities –identity level (A)	2025/05/25	General Assembly
8	Quantities –identity level (A)	2025/06/03	Other – Internal Procedures
9	Quantities –identity level (A)	2025/06/23	Other – Internal Procedures
10	Quantities –identity level (A)	2025/06/26	Other – Internal Procedures
11	Quantities –identity level (A)	2025/07/23	Other – Assembly Procedures
12	Quantities –identity level (A)	2025/07/28	Other – Internal Procedures
13	Quantities –identity level (A)	2025/08/05	Other – Internal Procedures
14	Quantities –identity level (A)	2025/08/26	Other – Internal Procedures
15	Quantities –identity level (A)	2025/08/31	Other – Internal Procedures
16	Quantities –identity level (A)	2025/10/09	Other – Internal Procedures
17	Quantities –identity level (A)	2025/11/05	Other – Internal Procedures
18	Quantities –identity level (A)	2025/12/14	Other – Internal Procedures

Company Disclosures during the Year 2025G

N	Company disclosures	Date
1	AME Company for Medical Supplies announces its annual financial results for the year ending December 31, 2024.	24/03/2025
2	AME Company for Medical Supplies announces the Board of Directors' recommendation to distribute dividends to shareholders for the fiscal year ending December 31, 2024.	24/03/2025
3	AME Company for Medical Supplies announces the Board of Directors' recommendation to terminate the current Board's term prematurely.	24/03/2025
4	Corrective announcement from AME Company for Medical Supplies regarding the annual financial results for the year ending December 31, 2024.	26/03/2025
5	The Board of Directors of AME Company for Medical Supplies invites shareholders to attend the Extraordinary General Assembly Meeting (First Meeting).	04/05/2025
6	Supplementary announcement from AME Company for Medical Supplies regarding the invitation to its shareholders to attend the Extraordinary General Assembly Meeting (First Meeting).	05/05/2025
7	AME Company for Medical Supplies announces the commencement of electronic voting on the agenda items of the Extraordinary General Assembly Meeting (First Meeting) using modern technology.	22/05/2025
8	AME Company for Medical Supplies announces the results of the Extraordinary General Assembly Meeting. (First Meeting)	26/05/2025
9	Supplementary Announcement from AME Company for Medical Supplies regarding the results of the Extraordinary General Assembly Meeting (First Meeting)	27/05/2025
10	Announcement from AME Company for Medical Supplies regarding the opening of nominations for membership on the Board of Directors	27/05/2025
11	The Board of Directors of AME Company for Medical Supplies invites shareholders to attend the Ordinary General Assembly Meeting (First Meeting)	06/07/2025
12	Announcement from AME Company for Medical Supplies regarding the results of the Ordinary General Assembly Meeting (First Meeting)	28/07/2025
13	Announcement from AME Company for Medical Supplies regarding the appointment of the Chairman and Vice Chairman of the Board of Directors, the formation of the board committees and the appointment of company representatives.	04/08/2025
14	Supplementary Announcement from AME Company for Medical Supplies regarding the formation of the Audit Committee	05/08/2025
15	Announcement from AME Company for Medical Supplies regarding the preliminary financial results for the period ending June 30, 2025G (six months)	31/08/2025

Board Declarations

1. The Company has not held any treasury shares during 2025G
2. The Company has not issued any debt instruments.
3. There are no debt instruments issued on behalf for the Company, and there are no interests, contractual documents, or subscription rights owned by the Board members, the Executive Management, or their relatives in its shares or any of its subsidiaries.
4. The Company has not issued or granted any debt instruments convertible into shares, contractual securities, option rights, subscription right notes or similar rights.
5. The Company does not have any transfer or subscription rights under any transferable debt instrument, contractual securities, guarantees or similar rights, whether issued or granted.
6. The Company did not issue any redeemable bonds, and accordingly the Company did not redeem, purchase or cancel any redeemable debt instruments.
7. There is no arrangement or agreement under which a shareholder of the Company waives any rights to profits.
8. There is no arrangement or agreement under which a member of the Board of Directors or a senior executive in the Company waives any rights to profits.
9. There are no investments or reserves created for the benefit of the employees by the company.
10. The consolidated financial statements have been prepared in accordance with international financial reporting standards and in accordance with the Company's regulations and Articles of Association with regard to the preparation and publication of the financial statements.
11. No deviations from the accounting standards adopted by the Saudi Organization for Auditors and Accountants were recorded.

12. The external auditor's report did not include any qualifications on the annual financial statements, and some comparative figures were reclassified to conform to the current presentation of the financial statements for the annual financial period ending 31/2025/12/G.
13. The Company did not receive any notes or opinions from the shareholders regarding the Company or its performance.
14. The Board of Directors recommended terminating the contract with the company's auditor, KPMG, due to its exhaustion of the maximum period permitted by regulation, in accordance with Article (3) of the Implementing Regulations of the Companies Law issued by the Capital Market Authority and related to listed joint-stock companies. Ernst & Young was appointed as the company's auditor to examine, review and audit the financial statements for the (second and third) quarters and the year of fiscal year 2025G. and for the (first, second and third) quarters and the year of fiscal year 2026, 2027, and to determine its fees.



Other Declarations

1. The Company's records of accounts have been prepared on a sound basis and approved by SOCPA.
2. The internal control system was is considered acceptable but needs to be developed and further activated based on the recommendation of the Review Committee.
3. There is no doubt over the Company's ability to continue as a going concern.



Compliance with Corporate Governance Regulation

The Board of Directors sets corporate governance rules that do not conflict with the mandatory provisions in the Corporate Governance Regulations and works to monitor their application, verify their effectiveness, and amend them when needed. In implementation of the provisions of the Corporate Governance Regulations issued by the Capital Market Authority, which requires the Company to disclose the provisions of this regulation that have been applied and the ones that have not been applied, along with an explanation of the reasons for non-compliance, in the Board of Directors' report. It should be noted here that (AME) Company has prepared its governance regulations in accordance with the requirements of the Corporate Governance Regulations issued by the Capital Market Authority, and update it periodically to ensure compliance with the Capital Market Law and its Implementing Regulations. The Company has committed to implementing all the provisions contained in these regulations, except for the following articles:

Article Number	Subparagraph Number	Article text	Notes	Reasons for non-compliance
37 (Training)	2, 1	<p>1) preparing programs for the recently-appointed Board members, committee members, and Executive Management to familiarize them with the progress of the Company's business and activities, particularly the following:</p> <ul style="list-style-type: none"> a. the strategy and objectives of the Company; b. the financial and operational aspects of the Company's activities; c. the obligations of the Board members and their duties, responsibilities and rights; d. the duties and competencies of the committees of the Board. <p>developing the necessary mechanisms for Board members, committee members, and the Executive Management to continuously enroll in training programmes and courses in order to develop their</p>	Guiding Article/ Clause	The company is in the process of developing a training mechanism to enhance the skills of board members, committees, and executive management.

Article Number	Subparagraph Number	Article text	Notes	Reasons for non-compliance
39 The Assessment		1. The Board shall develop, based on the proposal of the nomination committee, the necessary mechanisms to annually assess the performance of the Board, its members and committees and the Executive Management using key performance indicators linked to the extent to which the strategic objectives of the Company have been achieved, the quality of the risk management and the efficiency of the internal control systems, among others, provided that weaknesses and strengths shall be identified and a solution shall be proposed for the same in the best interests of the Company.	Guiding Article/ Clause	
		2. The procedures of performance assessment shall be in writing and clearly stated and disclosed to the Board members and parties concerned with the assessment.		
		3. The performance assessment shall entail an assessment of the skills and experiences of the Board, identification of the weaknesses and strengths of the Board and shall attempt to resolve such weaknesses using the available methods, such as nominating competent professional staff able to improve the performance of the Board. The performance assessment shall also entail the assessment of the mechanisms of the Board's activities in general.		

Article Number	Subparagraph Number	Article text	Notes	Reasons for non-compliance
67 Composition of the Risk Management Committee		The Company's Board shall, by resolution therefrom, form a committee to be named the "risk management committee.". Chairman and majority of its members shall be Non-Executive Directors. The members of that committee shall possess an adequate level of knowledge in risk management and finance.	Guiding Article/ Clause	
68 Competencies of the Risk Management Committee		All of the competencies of the risk management committee	Guiding Article/ Clause	
69 Meetings of the Risk Management Committee		The risk management committee shall convene periodically at least once every six months, and as may be necessary.	Guiding Article/ Clause	
84 Social Responsibility		The Ordinary General Assembly, based on the Board recommendation, shall establish a policy that guarantees a balance between its objectives and those of the community for purposes of developing the social and economic conditions of the community.	Guiding Article/ Clause	
85 Social Initiatives		The Board shall establish programmes and determine the necessary methods for proposing social initiatives by the Company,	Guiding Article/ Clause	
92 Formation of a Corporate Governance Committee		If the Board forms a corporate governance committee, it shall assign to it the competencies stipulated in Article (91) of these Regulations. Such committee shall oversee any matters relating to the implementation of governance, and shall provide the Board with its reports and recommendations at least annually.	Guiding Article/ Clause	



AME Company for Medical Supplies

AME